In this issue of Cell Reports, Li et al. show that the analysis of genetic changes in patient-derived xenografts can reveal crucial details of tumor evolution, such as the emergence of functional estrogen receptor mutations in endocrine-resistant breast cancer
Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who ...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
International audienceBreast cancer remains a major health issue in the world with 1.7 million new c...
In this issue of Cell Reports, Li et al. show that the analysis of genetic changes in patient-derive...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
The cancer genomics revolution has rapidly expanded the inventory of somatic mutations characterizin...
International audienceABSTRACT: INTRODUCTION: Identification of new therapeutic agents for breast ca...
SummaryCancer genomics has provided an unprecedented opportunity for understanding genetic causes of...
Introduction: Identification of new therapeutic agents for breast cancer (BC) requires preclinical m...
Cancer genomics has provided an unprecedented opportunity for understanding genetic causes of human ...
The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)geneti...
Humanization of the mouse mammary gland by replacement of the luminal layer with genetically human c...
AbstractHistologically accurate mouse models of human cancers generated by somatic or germline genet...
Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors ...
In developed countries, breast cancer is the commonest malignancy among women. Understanding the mec...
Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who ...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
International audienceBreast cancer remains a major health issue in the world with 1.7 million new c...
In this issue of Cell Reports, Li et al. show that the analysis of genetic changes in patient-derive...
Estrogen receptor-positive (ER+) tumors account for 70-80% of all breast cancer (BC) cases and are c...
The cancer genomics revolution has rapidly expanded the inventory of somatic mutations characterizin...
International audienceABSTRACT: INTRODUCTION: Identification of new therapeutic agents for breast ca...
SummaryCancer genomics has provided an unprecedented opportunity for understanding genetic causes of...
Introduction: Identification of new therapeutic agents for breast cancer (BC) requires preclinical m...
Cancer genomics has provided an unprecedented opportunity for understanding genetic causes of human ...
The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)geneti...
Humanization of the mouse mammary gland by replacement of the luminal layer with genetically human c...
AbstractHistologically accurate mouse models of human cancers generated by somatic or germline genet...
Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors ...
In developed countries, breast cancer is the commonest malignancy among women. Understanding the mec...
Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who ...
Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs...
International audienceBreast cancer remains a major health issue in the world with 1.7 million new c...